{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:19Z","timestamp":1778780119782,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":2320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Young Investigator Award"},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA143906"],"award-info":[{"award-number":["U54CA143906"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1093\/annonc\/mdt109","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T21:35:15Z","timestamp":1363901715000},"page":"1900-1907","source":"Crossref","is-referenced-by-count":45,"title":["Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates"],"prefix":"10.1016","volume":"24","author":[{"given":"R.K.","family":"Kelley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.S.","family":"Nimeiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.N.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"Vergo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Luttgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Grabowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Stucky-Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.M.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.K.","family":"Bergsland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"A.B.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.P.","family":"Venook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt109_bb0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt109_bb0015","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4000","article-title":"Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). In American Society of Clinical Oncology Annual Meeting. Chicago, IL","author":"Cheng","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt109_bb0020","article-title":"Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study","author":"Llovet","year":"2012","journal-title":"International Liver Congress, European Association for the Study of the Liver"},{"key":"10.1093\/annonc\/mdt109_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)34320-9","article-title":"SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC)","author":"Zhu","year":"2012","journal-title":"37th ESMO Congress, European Society of Medical Oncology"},{"key":"10.1093\/annonc\/mdt109_bb0030","doi-asserted-by":"crossref","first-page":"ra24","DOI":"10.1126\/scisignal.2002739","article-title":"Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice","volume":"5","author":"Menon","year":"2012","journal-title":"Sci Signal"},{"key":"10.1093\/annonc\/mdt109_bb0035","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdt109_bb0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12032-009-9201-4","article-title":"The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma","volume":"27","author":"Zhou","year":"2010","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdt109_bb0045","article-title":"RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma","author":"Huynh","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1093\/annonc\/mdt109_bb0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2006.11.021","article-title":"Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma","volume":"46","author":"Semela","year":"2007","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt109_bb0055","article-title":"Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma","author":"Wang","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdt109_bb0060","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.dld.2012.02.005","article-title":"Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma","volume":"44","author":"Decaens","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1093\/annonc\/mdt109_bb0065","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt109_bb0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/lt.22441","article-title":"Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"18","author":"Liang","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1093\/annonc\/mdt109_bb0075","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/j.1582-4934.2009.00692.x","article-title":"Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma","volume":"13","author":"Huynh","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1093\/annonc\/mdt109_bb0080","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jhep.2008.08.010","article-title":"ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft","volume":"49","author":"Jasinghe","year":"2008","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt109_bb0085","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-07-4774","article-title":"Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma","volume":"14","author":"Wang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt109_bb0090","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-10-0666","article-title":"Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma","volume":"10","author":"Piguet","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdt109_bb0095","doi-asserted-by":"crossref","first-page":"e33379","DOI":"10.1371\/journal.pone.0033379","article-title":"Activation of PI3K\/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdt109_bb0100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2009.03.028","article-title":"Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo","volume":"51","author":"Newell","year":"2009","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt109_bb0105","first-page":"2531","article-title":"The role of PI3K\/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment","volume":"32","author":"Gedaly","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdt109_bb0110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jss.2011.10.045","article-title":"PKI-587 and sorafenib targeting PI3K\/AKT\/mTOR and Ras\/Raf\/MAPK pathways synergistically inhibit HCC cell proliferation","volume":"176","author":"Gedaly","year":"2012","journal-title":"J Surg Res"},{"key":"10.1093\/annonc\/mdt109_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4074","article-title":"Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). In American Society of Clinical Oncology Annual Meeting. Chicago, IL","author":"Finn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt109_bb0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Gomez-Martin","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1093\/annonc\/mdt109_bb0125","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1078-0432.CCR-10-2061","article-title":"Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies","volume":"17","author":"Gangadhar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt109_bb0130","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.25931","article-title":"A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma","volume":"117","author":"Harzstark","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt109_bb0135","author":"Sarantopoulos","year":"2011","journal-title":"Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study"},{"key":"10.1093\/annonc\/mdt109_bb0140","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdt109_bb0145","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10337-012-2341-2","article-title":"A simple and sensitive LC-MS\/MS method for simultaneous determination of temsirolimus and its major metabolite in human whole blood","volume":"75","author":"Zhang","year":"2012","journal-title":"Chromatographia"},{"key":"10.1093\/annonc\/mdt109_bb0150","unstructured":"BayerInvestigator's Brochure BAY 43\u20139006Version 12.0 Edition. 2011; 192"},{"key":"10.1093\/annonc\/mdt109_bb0155","first-page":"40","article-title":"Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis","volume":"4","author":"Abou-Alfa","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"10.1093\/annonc\/mdt109_bb0160","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt109_bb0165","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdt109_bb0170","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43\u20139006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt109_bb0175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt109_bb0180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jhep.2012.02.016","article-title":"Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma","volume":"57","author":"Personeni","year":"2012","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt109_bb0185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cgh.2008.08.041","article-title":"Utility of lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma","volume":"7","author":"Sterling","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1093\/annonc\/mdt109_bb0190","doi-asserted-by":"crossref","first-page":"016001","DOI":"10.1088\/1478-3975\/9\/1\/016001","article-title":"Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors","volume":"9","author":"Cho","year":"2012","journal-title":"Phys Biol"},{"key":"10.1093\/annonc\/mdt109_bb0195","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4254\/wjh.v4.i5.158","article-title":"Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis","volume":"4","author":"Bunchorntavakul","year":"2012","journal-title":"World J Hepatol"},{"key":"10.1093\/annonc\/mdt109_bb0200","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1158\/1078-0432.CCR-11-2436","article-title":"Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma","volume":"18","author":"Davies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt109_bb0205","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/1078-0432.CCR-11-2488","article-title":"Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438)","volume":"18","author":"Margolin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt109_bb0210","year":"2012","journal-title":"Torisel Full Prescribing Information"},{"key":"10.1093\/annonc\/mdt109_bb0215","year":"2011","journal-title":"Nexavar Highlights of Prescribing Information"},{"key":"10.1093\/annonc\/mdt109_bb0220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2008.18.8151","article-title":"New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"27","author":"Chan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt109_bb0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000334454","article-title":"Early decrease in alpha-fetoprotein, but not des-gamma-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma","volume":"81","author":"Kuzuya","year":"2011","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdt109_bb0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/7\/1900\/13789434\/mdt109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T03:38:39Z","timestamp":1624678719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419366542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0923753419366542"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt109","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717995464.793474230","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717995464.793475918","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}